A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer's disease (REFLECT-3).

Trial Profile

A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer's disease (REFLECT-3).

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms REFLECT-3
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 09 Mar 2010 Actual patient number changed from 1429 to 1450 as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Jul 2009 Results presented at the 2009 International Conference on Alzheimer's Disease (ICAD).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top